Zimbabwe has turned down a substantial American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to Washington's request for confidential data.
This rejection came to light following a internal memorandum from December was leaked, which showed President Emmerson Mnangagwa felt the deal was "skewed".
An official spokesperson has since clarified that the US was requesting genetic material for research and commercial purposes while was unwilling to guarantee the resulting advantages from future medical innovations.
"We will now turn to the challenging and unfortunate process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for more negotiations to reach a deal acceptable to both sides so the country's vital HIV programme can continue.
Wider Implications
This rejection comes after a similar case in Kenya, where a high court halted a similar health funding agreement after concerns were filed about the safety of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government agreements to enhance openness and accountability.
As per reports, 16 African countries have to date agreed to similar health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, without any equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our people should a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending systems already established through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage future pandemics.
"This mechanism is designed to ensure that when a country provides its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how subsequent co-operation could be structured in a manner that honours the independence and interests of each country."
Medical Community Reaction
Medical experts said it acknowledged the government's concerns, but recommended that negotiations need to persist considering much of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns exist, such as those involving information security or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," the group commented.
The situation underscores the complex challenges between receiving crucial foreign assistance and safeguarding local interests in an ever more interconnected world.